BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azimirad M, Krutova M, Balaii H, Kodori M, Shahrokh S, Azizi O, Yadegar A, Aghdaei HA, Zali MR. Coexistence of Clostridioides difficile and Staphylococcus aureus in gut of Iranian outpatients with underlying inflammatory bowel disease. Anaerobe 2020;61:102113. [DOI: 10.1016/j.anaerobe.2019.102113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gholam-mostafaei FS, Yadegar A, Aghdaei HA, Azimirad M, Daryani NE, Zali MR. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease. Current Research in Translational Medicine 2020;68:125-30. [DOI: 10.1016/j.retram.2020.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Abdehagh M, Azimirad M, Houri H, Nadalian B, Azimirad F, Olfatifar M, Nasir Shoeibi OK, Yadegar A, Shahrokh S, Mahdavi Roshan M, Asadzadeh Aghdaei H, Zali MR. Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease. BMC Infect Dis 2021;21:1103. [PMID: 34702217 DOI: 10.1186/s12879-021-06804-2] [Reference Citation Analysis]
3 Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdaei H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res 2020;13:563-70. [PMID: 32982371 DOI: 10.2147/JIR.S265520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kodori M, Ghalavand Z, Yadegar A, Eslami G, Azimirad M, Krutova M, Abadi A, Zali MR. Molecular characterization of pathogenicity locus (PaLoc) and tcdC genetic diversity among tcdA+B+Clostridioides difficile clinical isolates in Tehran, Iran. Anaerobe 2020;66:102294. [PMID: 33181348 DOI: 10.1016/j.anaerobe.2020.102294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Li X, Laura H, Wolter N, Li H, Shi X, Pich A. Charge-reversible and biodegradable chitosan-based microgels for lysozyme-triggered release of vancomycin. Journal of Advanced Research 2022. [DOI: 10.1016/j.jare.2022.02.014] [Reference Citation Analysis]
6 Brajerova M, Zikova J, Krutova M. Clostridioides difficile epidemiology in the Middle and the Far East. Anaerobe 2022;:102542. [PMID: 35240336 DOI: 10.1016/j.anaerobe.2022.102542] [Reference Citation Analysis]
7 Azimirad M, Krutova M, Yadegar A, Shahrokh S, Olfatifar M, Aghdaei HA, Fawley WN, Wilcox MH, Zali MR. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect 2020;9:1432-43. [PMID: 32520657 DOI: 10.1080/22221751.2020.1780949] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Noori Goodarzi N, Fereshteh S, Azizi O, Rahimi H, Bolourchi N, Badmasti F. Subtractive genomic approach toward introduction of novel immunogenic targets against Clostridioides difficile: Thinking out of the box. Microb Pathog 2021;162:105372. [PMID: 34954046 DOI: 10.1016/j.micpath.2021.105372] [Reference Citation Analysis]
9 Noori M, Ghalavand Z, Azimirad M, Yadegar A, Eslami G, Krutova M, Brajerova M, Goudarzi M, Zali MR. Genetic diversity and phylogenetic analysis of the surface layer protein A gene (slpA) among Clostridioides difficile clinical isolates from Tehran, Iran. Anaerobe 2021;70:102403. [PMID: 34111549 DOI: 10.1016/j.anaerobe.2021.102403] [Reference Citation Analysis]